Samsung Biologics wins $1.4 bil. manufacturing deal in Europe

Samsung Biologics's No. 4 plant in Incheon / Courtesy of Samsung Biologics
Samsung Biologics, a biotech arm of Korea's Samsung Group, said Tuesday it has received a contract manufacturing deal worth 2.07 trillion won ($1.4 billion) from a Europe-based biopharmaceutical firm.
In the largest-ever contract manufacturing deal, Samsung Biologics will manufacture a biomedicine for the European company from Dec. 13, 2024, through Dec. 31, 2030, the company said in a regulatory filing.
The company didn't provide the name of the medicine or the contractor.
The latest deal represents 40 percent of Samsung Biologics' overall contracts won last year, worth 5.4 trillion won. (Yonhap)